A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.

Trial Profile

A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Elvucitabine (Primary) ; Efavirenz; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 17 Feb 2010 96-week final results will be presented at the 17th Conference on Retroviruses and Opportunistic Infections, according to an Achillion Pharmaceuticals media release.
    • 16 Feb 2010 96-week follow-up results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
    • 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top